# More **comprehensive information** for better **treatment decisions.**

Prosigna®
BREAST CANCER ASSAY

Provides more accurate prognosis which is the **foundation of treatment recommendations**[1].

Prosigna® combines **tumour gene expression and clinico-pathological factors** in a single 10-year Risk of distant Recurrence (ROR) score[2,3].

The only breast cancer prognostic test identifying the **four PAM50 molecular subtypes**.

Easy access to local testing with **faster turnaround times**.

1. Sestak I, Buus R, Cuzick J, *et al.* JAMA Oncol. 2018; 4(4):545–553
2. Kos *et al.* Breast Cancer Res, 2014, 16:103
3. Alexandre *et al.* Cancer Manag Res, 2019; 11: 10353–10373

Prosigna®
BREAST CANCER ASSAY

2nd generation test
that more comprehensively **informs treatment decisions.**

CE-IVD MARKED

GUIDELINES RECOMMENDED

More Accurate Prognostic Score

Intrinsic Subtype Identified

Clinico-pathological Factors Integrated

บริษัท พริมา ไซเอ็นติฟิค จำกัด
147/170-171 ถ.บรมราชชนนี อรุณอมรินทร์
บางกอกน้อย กรุงเทพฯ 10700
Tel : (02) 435-7434 , 434-3771 , 433-2081 Fax : (02) 884-6441
E-mail : primasci@primasci.com ; Website : www.prima-sci.com

veracyte

PS
บริษัท พริมา ไซเอ็นติฟิค จำกัด

veracyte

Prosigna® more accurately identifies the low-risk group with better outcomes and the high-risk group with worse outcomes[1].

2nd GENERATION ASSAY
(Prosigna®)

- 50 genes
- Gene expression + clinical features
- Local testing

27% of patients are **Low Risk** with 92.3% rate of DRFS*

38% of patients are **Int. Risk** with 79.6% rate of DRFS*

35% of patients are **High Risk** with 69.9% rate of DRFS*

● ● ● No recurrence
○ ○ ○ Recurrence

10 YEARS PROGNOSIS

1st GENERATION ASSAY

- 21 genes
- Gene expression only
- Samples need to be sent to the US

**50%** of patients are **Low Risk** with 85.4% rate of DRFS*

31% of patients are **Int. Risk** with 79.8% rate of DRFS*

19% of patients are **High Risk** with 74.9% rate of DRFS*

● ● ● No recurrence
○ ○ ○ Recurrence

5 YEARS PROGNOSIS

Clinically Validated Algorithm Generates a Prosigna® Score for Each Patient.

Patient expression profile	Prosigna centroids	Nodal Status	Prosigna® Score =	Patient Report

Prosigna centroids: LumB, LumA, Basal-like, HER2-enriched

Nodal Status
Node 0
Node 1-3

Gross Tumour size
<2cm
≥2cm

Prosigna® Score =

aR_{LumA} +
bR_{LumB} +
cR_{Her2e} +
dR_{Basal} +

Pearson's correlation to centroids

eP +
fT

Proliferation score & Gross tumour size

Patient Report

How does the Prosigna® Assay work?

1
Extract RNA from FFPE* tumour sample

2
Test RNA using Prosigna® Assay on the nCounter Analysis System

3
Capture expression profile of patient's tumour

MKI67
CCNE1
ORH7
TMEM45B
ERBB2
BLVRA
GPR160
FOXA1
MMP11
NAT1
CXXC5
ESR1
SLC39A6

4
Patient Report
- **Intrinsic Subtype identified**
- **Risk of Recurence (ROR)** within **10 years**
- **Risk of Recurence (ROR) 5-10 years** (late relapse)
- **Clinicopathological factors** like tumour size and nodal status incorporated in the score

---

*DRFS: Distant Recurrence Free Survival.
The probability of developing recurrence were obtained from a bespoke data analysis of the TransATAC study (Sestak I, Dowsett M, Cuzick J. NICE Request – TransATAC Data Analysis –2017. Illustration adapted from Harnan S, *et al*. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer Health Technol Assess. 2019 Jun;23(30):1-328.

*FFPE: Formalin Fixed Paraffin Embedded Tissue.